US20220096502A1 - Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy - Google Patents
Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy Download PDFInfo
- Publication number
- US20220096502A1 US20220096502A1 US17/549,475 US202117549475A US2022096502A1 US 20220096502 A1 US20220096502 A1 US 20220096502A1 US 202117549475 A US202117549475 A US 202117549475A US 2022096502 A1 US2022096502 A1 US 2022096502A1
- Authority
- US
- United States
- Prior art keywords
- mitochondrial
- compound
- doxycycline
- mitochondrial biogenesis
- cscs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010021143 Hypoxia Diseases 0.000 title claims abstract description 83
- 229960003722 doxycycline Drugs 0.000 title claims abstract description 26
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 25
- 230000001146 hypoxic effect Effects 0.000 title claims abstract description 23
- 201000011510 cancer Diseases 0.000 title claims abstract description 19
- 210000000130 stem cell Anatomy 0.000 title claims description 11
- 238000011122 anti-angiogenic therapy Methods 0.000 title description 4
- 230000008685 targeting Effects 0.000 title description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 claims abstract description 48
- 230000008437 mitochondrial biogenesis Effects 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 27
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims abstract description 25
- 239000004098 Tetracycline Substances 0.000 claims abstract description 11
- 239000004037 angiogenesis inhibitor Substances 0.000 claims abstract description 11
- 235000019364 tetracycline Nutrition 0.000 claims abstract description 11
- 150000003522 tetracyclines Chemical class 0.000 claims abstract description 11
- 238000002512 chemotherapy Methods 0.000 claims abstract description 9
- -1 doxycycline Chemical class 0.000 claims abstract description 7
- 230000001235 sensitizing effect Effects 0.000 claims abstract description 7
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 15
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 15
- 229960003787 sorafenib Drugs 0.000 claims description 14
- DZLOHEOHWICNIL-QGZVFWFLSA-N (2R)-2-[6-(4-chlorophenoxy)hexyl]-2-oxiranecarboxylic acid ethyl ester Chemical compound C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)OCC)CO1 DZLOHEOHWICNIL-QGZVFWFLSA-N 0.000 claims description 13
- 229950006213 etomoxir Drugs 0.000 claims description 13
- CYXKNKQEMFBLER-UHFFFAOYSA-N perhexiline Chemical compound C1CCCNC1CC(C1CCCCC1)C1CCCCC1 CYXKNKQEMFBLER-UHFFFAOYSA-N 0.000 claims description 13
- 229960000989 perhexiline Drugs 0.000 claims description 13
- LDBPIZIYTBIRPM-VQHVLOKHSA-N phenyl (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OC1=CC=CC=C1 LDBPIZIYTBIRPM-VQHVLOKHSA-N 0.000 claims description 12
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 10
- NZJKEVWTYMOYOR-UHFFFAOYSA-N 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanylidene-1h-quinazolin-4-one Chemical compound C1=C(Cl)C(OC)=CC(N2C(C3=CC=CC=C3NC2=S)=O)=C1Cl NZJKEVWTYMOYOR-UHFFFAOYSA-N 0.000 claims description 10
- 229960003159 atovaquone Drugs 0.000 claims description 10
- KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 claims description 10
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 10
- 229960004099 azithromycin Drugs 0.000 claims description 10
- QUIJNHUBAXPXFS-XLJNKUFUSA-N bedaquiline Chemical compound C1([C@H](C2=CC3=CC(Br)=CC=C3N=C2OC)[C@@](O)(CCN(C)C)C=2C3=CC=CC=C3C=CC=2)=CC=CC=C1 QUIJNHUBAXPXFS-XLJNKUFUSA-N 0.000 claims description 10
- 229960000508 bedaquiline Drugs 0.000 claims description 10
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims description 10
- 229940093265 berberine Drugs 0.000 claims description 10
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims description 10
- 229960003677 chloroquine Drugs 0.000 claims description 10
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 10
- 229960004768 irinotecan Drugs 0.000 claims description 10
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 10
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 claims description 10
- 229960001920 niclosamide Drugs 0.000 claims description 10
- IBLNKMRFIPWSOY-FNORWQNLSA-N stiripentol Chemical compound CC(C)(C)C(O)\C=C\C1=CC=C2OCOC2=C1 IBLNKMRFIPWSOY-FNORWQNLSA-N 0.000 claims description 10
- 229960001897 stiripentol Drugs 0.000 claims description 10
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims description 9
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 claims description 9
- OOPDAHSJBRZRPH-UHFFFAOYSA-L Pyrvinium pamoate Chemical compound C1=CC2=CC(N(C)C)=CC=C2[N+](C)=C1C=CC(=C1C)C=C(C)N1C1=CC=CC=C1.C1=CC2=CC(N(C)C)=CC=C2[N+](C)=C1C=CC(=C1C)C=C(C)N1C1=CC=CC=C1.C12=CC=CC=C2C=C(C([O-])=O)C(O)=C1CC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 OOPDAHSJBRZRPH-UHFFFAOYSA-L 0.000 claims description 9
- 229960002626 clarithromycin Drugs 0.000 claims description 9
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 9
- 229960004023 minocycline Drugs 0.000 claims description 9
- 229960001077 pyrvinium pamoate Drugs 0.000 claims description 9
- 229960002180 tetracycline Drugs 0.000 claims description 9
- 229930101283 tetracycline Natural products 0.000 claims description 9
- 229960004089 tigecycline Drugs 0.000 claims description 9
- 229930012538 Paclitaxel Natural products 0.000 claims description 8
- 102000002938 Thrombospondin Human genes 0.000 claims description 8
- 108060008245 Thrombospondin Proteins 0.000 claims description 8
- 229960001592 paclitaxel Drugs 0.000 claims description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 5
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 5
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 5
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 5
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 4
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 4
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 claims description 4
- 102400000068 Angiostatin Human genes 0.000 claims description 4
- 108010079709 Angiostatins Proteins 0.000 claims description 4
- 108010079505 Endostatins Proteins 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 4
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 claims description 4
- 102000004211 Platelet factor 4 Human genes 0.000 claims description 4
- 108090000778 Platelet factor 4 Proteins 0.000 claims description 4
- 102000003946 Prolactin Human genes 0.000 claims description 4
- 108010057464 Prolactin Proteins 0.000 claims description 4
- 108091008605 VEGF receptors Proteins 0.000 claims description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 4
- 230000000964 angiostatic effect Effects 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims description 4
- 229960000397 bevacizumab Drugs 0.000 claims description 4
- WNRZHQBJSXRYJK-UHFFFAOYSA-N carboxyamidotriazole Chemical compound NC1=C(C(=O)N)N=NN1CC(C=C1Cl)=CC(Cl)=C1C(=O)C1=CC=C(Cl)C=C1 WNRZHQBJSXRYJK-UHFFFAOYSA-N 0.000 claims description 4
- 229960005167 everolimus Drugs 0.000 claims description 4
- 229960002897 heparin Drugs 0.000 claims description 4
- 229920000669 heparin Polymers 0.000 claims description 4
- 229960004130 itraconazole Drugs 0.000 claims description 4
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims description 4
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims description 4
- 229960000639 pazopanib Drugs 0.000 claims description 4
- 229940097325 prolactin Drugs 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 229960002633 ramucirumab Drugs 0.000 claims description 4
- 229960003876 ranibizumab Drugs 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- 229960001796 sunitinib Drugs 0.000 claims description 4
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 4
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 claims description 4
- 229960005314 suramin Drugs 0.000 claims description 4
- 229960003433 thalidomide Drugs 0.000 claims description 4
- SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 claims description 3
- 229960003522 roquinimex Drugs 0.000 claims description 3
- ONDYALNGTUAJDX-UHFFFAOYSA-N tasquinimod Chemical compound OC=1C=2C(OC)=CC=CC=2N(C)C(=O)C=1C(=O)N(C)C1=CC=C(C(F)(F)F)C=C1 ONDYALNGTUAJDX-UHFFFAOYSA-N 0.000 claims description 3
- 229950001899 tasquinimod Drugs 0.000 claims description 3
- CXVCSRUYMINUSF-UHFFFAOYSA-N tetrathiomolybdate(2-) Chemical compound [S-][Mo]([S-])(=S)=S CXVCSRUYMINUSF-UHFFFAOYSA-N 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 10
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 102400001047 Endostatin Human genes 0.000 claims 2
- 230000008436 biogenesis Effects 0.000 abstract description 4
- 229940040944 tetracyclines Drugs 0.000 abstract description 2
- 230000004898 mitochondrial function Effects 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 description 60
- 210000004027 cell Anatomy 0.000 description 45
- 230000000694 effects Effects 0.000 description 31
- 230000001684 chronic effect Effects 0.000 description 27
- 230000002438 mitochondrial effect Effects 0.000 description 24
- 238000011282 treatment Methods 0.000 description 21
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 18
- 230000004563 mammosphere formation Effects 0.000 description 14
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 12
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 12
- 238000013459 approach Methods 0.000 description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 230000002503 metabolic effect Effects 0.000 description 9
- 229960000604 valproic acid Drugs 0.000 description 9
- 239000003642 reactive oxygen metabolite Substances 0.000 description 8
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 5
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 101000798951 Homo sapiens Mitochondrial import receptor subunit TOM20 homolog Proteins 0.000 description 4
- 102100020755 Hypoxia up-regulated protein 1 Human genes 0.000 description 4
- 101710120772 Hypoxia up-regulated protein 1 Proteins 0.000 description 4
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 4
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 4
- 102100034007 Mitochondrial import receptor subunit TOM20 homolog Human genes 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000034659 glycolysis Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 230000007959 normoxia Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 102100021403 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing], mitochondrial Human genes 0.000 description 3
- 102100021388 3-hydroxyisobutyrate dehydrogenase, mitochondrial Human genes 0.000 description 3
- 102100030362 Acyl-coenzyme A synthetase ACSM2B, mitochondrial Human genes 0.000 description 3
- 102100025845 Acyl-coenzyme A thioesterase 9, mitochondrial Human genes 0.000 description 3
- 102100024853 Carnitine O-palmitoyltransferase 2, mitochondrial Human genes 0.000 description 3
- 102100021645 Complex I assembly factor ACAD9, mitochondrial Human genes 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 101001041661 Homo sapiens 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing], mitochondrial Proteins 0.000 description 3
- 101000773360 Homo sapiens Acyl-coenzyme A synthetase ACSM2B, mitochondrial Proteins 0.000 description 3
- 101000720385 Homo sapiens Acyl-coenzyme A thioesterase 9, mitochondrial Proteins 0.000 description 3
- 101000909313 Homo sapiens Carnitine O-palmitoyltransferase 2, mitochondrial Proteins 0.000 description 3
- 101000677550 Homo sapiens Complex I assembly factor ACAD9, mitochondrial Proteins 0.000 description 3
- 101001083553 Homo sapiens Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Proteins 0.000 description 3
- 101000760730 Homo sapiens Medium-chain specific acyl-CoA dehydrogenase, mitochondrial Proteins 0.000 description 3
- 101001098982 Homo sapiens Propionyl-CoA carboxylase beta chain, mitochondrial Proteins 0.000 description 3
- 101000929936 Homo sapiens Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial Proteins 0.000 description 3
- 101000661451 Homo sapiens Succinate-CoA ligase [GDP-forming] subunit beta, mitochondrial Proteins 0.000 description 3
- 101000760747 Homo sapiens Very long-chain specific acyl-CoA dehydrogenase, mitochondrial Proteins 0.000 description 3
- 102100030358 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Human genes 0.000 description 3
- 102100024590 Medium-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 3
- 102100039025 Propionyl-CoA carboxylase beta chain, mitochondrial Human genes 0.000 description 3
- 102100035766 Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 3
- 102100037788 Succinate-CoA ligase [GDP-forming] subunit beta, mitochondrial Human genes 0.000 description 3
- 102100024591 Very long-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 2
- MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 description 2
- MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 description 2
- MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 2
- FLCWJWNCSHIREG-UHFFFAOYSA-N 2-(diethylamino)benzaldehyde Chemical compound CCN(CC)C1=CC=CC=C1C=O FLCWJWNCSHIREG-UHFFFAOYSA-N 0.000 description 2
- 102100024385 28S ribosomal protein S35, mitochondrial Human genes 0.000 description 2
- 101710107190 3-hydroxyisobutyrate dehydrogenase, mitochondrial Proteins 0.000 description 2
- 102100039776 39S ribosomal protein L4, mitochondrial Human genes 0.000 description 2
- 102100033750 39S ribosomal protein L47, mitochondrial Human genes 0.000 description 2
- MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 2
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 2
- 102100028814 ATP synthase mitochondrial F1 complex assembly factor 1 Human genes 0.000 description 2
- 102100027782 ATP synthase-coupling factor 6, mitochondrial Human genes 0.000 description 2
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 2
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 2
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 2
- 102100024745 DNA-directed RNA polymerase, mitochondrial Human genes 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 241001559542 Hippocampus hippocampus Species 0.000 description 2
- 101000689823 Homo sapiens 28S ribosomal protein S35, mitochondrial Proteins 0.000 description 2
- 101000667416 Homo sapiens 39S ribosomal protein L4, mitochondrial Proteins 0.000 description 2
- 101000733895 Homo sapiens 39S ribosomal protein L47, mitochondrial Proteins 0.000 description 2
- 101000883686 Homo sapiens 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 2
- 101000789413 Homo sapiens ATP synthase mitochondrial F1 complex assembly factor 1 Proteins 0.000 description 2
- 101000936965 Homo sapiens ATP synthase-coupling factor 6, mitochondrial Proteins 0.000 description 2
- 101000966742 Homo sapiens Leucine-rich PPR motif-containing protein, mitochondrial Proteins 0.000 description 2
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 description 2
- 101001111187 Homo sapiens NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial Proteins 0.000 description 2
- 101000674040 Homo sapiens Serine-tRNA ligase, mitochondrial Proteins 0.000 description 2
- 101000903318 Homo sapiens Stress-70 protein, mitochondrial Proteins 0.000 description 2
- 101000860835 Homo sapiens Ubiquinone biosynthesis protein COQ9, mitochondrial Proteins 0.000 description 2
- 102100040589 Leucine-rich PPR motif-containing protein, mitochondrial Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 102100031955 Lon protease homolog, mitochondrial Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 2
- 102100023964 NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial Human genes 0.000 description 2
- 108091006703 SLC25A1 Proteins 0.000 description 2
- 102100040597 Serine-tRNA ligase, mitochondrial Human genes 0.000 description 2
- 102100022760 Stress-70 protein, mitochondrial Human genes 0.000 description 2
- 102100036216 Tricarboxylate transport protein, mitochondrial Human genes 0.000 description 2
- 102100025336 Tyrosine-tRNA ligase, mitochondrial Human genes 0.000 description 2
- 102100028230 Ubiquinone biosynthesis protein COQ9, mitochondrial Human genes 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000011254 conventional chemotherapy Methods 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006539 extracellular acidification Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000022886 mitochondrial translation Effects 0.000 description 2
- 229930191479 oligomycin Natural products 0.000 description 2
- MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- 229940044192 2-hydroxyethyl methacrylate Drugs 0.000 description 1
- 108020003281 3-hydroxyisobutyrate dehydrogenase Proteins 0.000 description 1
- 102100035923 4-aminobutyrate aminotransferase, mitochondrial Human genes 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 description 1
- 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 description 1
- 102100040439 Adenylate kinase 4, mitochondrial Human genes 0.000 description 1
- UIFFUZWRFRDZJC-UHFFFAOYSA-N Antimycin A1 Natural products CC1OC(=O)C(CCCCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-UHFFFAOYSA-N 0.000 description 1
- NQWZLRAORXLWDN-UHFFFAOYSA-N Antimycin-A Natural products CCCCCCC(=O)OC1C(C)OC(=O)C(NC(=O)c2ccc(NC=O)cc2O)C(C)OC(=O)C1CCCC NQWZLRAORXLWDN-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100030297 Calcium uptake protein 1, mitochondrial Human genes 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- 102100036290 Calcium-binding mitochondrial carrier protein SCaMC-1 Human genes 0.000 description 1
- 101710189678 Calcium-binding mitochondrial carrier protein SCaMC-1 Proteins 0.000 description 1
- BMZRVOVNUMQTIN-UHFFFAOYSA-N Carbonyl Cyanide para-Trifluoromethoxyphenylhydrazone Chemical compound FC(F)(F)OC1=CC=C(NN=C(C#N)C#N)C=C1 BMZRVOVNUMQTIN-UHFFFAOYSA-N 0.000 description 1
- 102100037021 Citrate synthase, mitochondrial Human genes 0.000 description 1
- 101710195882 Citrate synthase, mitochondrial Proteins 0.000 description 1
- 102100023376 Corrinoid adenosyltransferase Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 101710150646 DNA-directed RNA polymerase, mitochondrial Proteins 0.000 description 1
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 1
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Natural products O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 102100031627 Evolutionarily conserved signaling intermediate in Toll pathway, mitochondrial Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 229940124602 FDA-approved drug Drugs 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102100025960 Glutaminase kidney isoform, mitochondrial Human genes 0.000 description 1
- 101710136238 Glutaminase kidney isoform, mitochondrial Proteins 0.000 description 1
- 102000042775 Heat shock protein 70 family Human genes 0.000 description 1
- 108091082017 Heat shock protein 70 family Proteins 0.000 description 1
- 101000727483 Homo sapiens 28S ribosomal protein S28, mitochondrial Proteins 0.000 description 1
- 101001000686 Homo sapiens 4-aminobutyrate aminotransferase, mitochondrial Proteins 0.000 description 1
- 101000991050 Homo sapiens Calcium uptake protein 1, mitochondrial Proteins 0.000 description 1
- 101001114650 Homo sapiens Corrinoid adenosyltransferase Proteins 0.000 description 1
- 101000686765 Homo sapiens DNA-directed RNA polymerase, mitochondrial Proteins 0.000 description 1
- 101000871228 Homo sapiens Diablo IAP-binding mitochondrial protein Proteins 0.000 description 1
- 101000866489 Homo sapiens Evolutionarily conserved signaling intermediate in Toll pathway, mitochondrial Proteins 0.000 description 1
- 101001042038 Homo sapiens Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 description 1
- 101000985328 Homo sapiens Methenyltetrahydrofolate cyclohydrolase Proteins 0.000 description 1
- 101001013097 Homo sapiens Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial Proteins 0.000 description 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- 101001021103 Homo sapiens Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial Proteins 0.000 description 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 102100021311 Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102100028687 Methenyltetrahydrofolate cyclohydrolase Human genes 0.000 description 1
- 102100029676 Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial Human genes 0.000 description 1
- 102100021769 Mitochondrial 2-oxoglutarate/malate carrier protein Human genes 0.000 description 1
- 101710142211 Mitochondrial 2-oxoglutarate/malate carrier protein Proteins 0.000 description 1
- 102100023727 Mitochondrial antiviral-signaling protein Human genes 0.000 description 1
- 101710142315 Mitochondrial antiviral-signaling protein Proteins 0.000 description 1
- 102100030105 Mitochondrial ornithine transporter 2 Human genes 0.000 description 1
- 108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102100038943 NAD(P) transhydrogenase, mitochondrial Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102100036201 Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial Human genes 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108091006711 SLC25A2 Proteins 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108091008852 Waterwitch Proteins 0.000 description 1
- 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 description 1
- BOPGDPNILDQYTO-NDOGXIPWSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3r,4r,5r)-5-(3-carbamoyl-4h-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NDOGXIPWSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940042992 afinitor Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- UIFFUZWRFRDZJC-SBOOETFBSA-N antimycin A Chemical compound C[C@H]1OC(=O)[C@H](CCCCCC)[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@H]1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-SBOOETFBSA-N 0.000 description 1
- PVEVXUMVNWSNIG-UHFFFAOYSA-N antimycin A3 Natural products CC1OC(=O)C(CCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O PVEVXUMVNWSNIG-UHFFFAOYSA-N 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006617 autophagic digestion Effects 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- NKLHEMWEQJCPPF-OKJGWHJPSA-M cob(I)yrinic acid a,c diamide Chemical compound N([C@@]([C@@]([C@@H]1CCC(O)=O)(C)CC(N)=O)(C)[C@@H]2N([Co])/C([C@]([C@H]2CC(O)=O)(C)CCC(O)=O)=C(/C)\C2=N\C(C([C@@H]2CCC(O)=O)(C)C)=C/2)=C1C(/C)=C\1[C@](CC(N)=O)(C)[C@H](CCC(O)=O)C\2=N/1 NKLHEMWEQJCPPF-OKJGWHJPSA-M 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 1
- 229960000936 fumagillin Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000021125 mitochondrion degradation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000019261 negative regulation of glycolysis Effects 0.000 description 1
- 229940080607 nexavar Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000005312 nonlinear dynamic Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000007055 protein processing involved in protein targeting to mitochondrion Effects 0.000 description 1
- 238000004725 rapid separation liquid chromatography Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 229940080817 rotenone Drugs 0.000 description 1
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 229940069559 votrient Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present disclosure relates to methods of eradicating hypoxic cancer stem cells using inhibitors of mitochondrial biogenesis with anti-angiogenic therapies, and to methods of sensitizing hypoxic cancer cells to chemotherapies by treating the cells with one or more mitochondrial biogenesis inhibitors.
- cancer therapies e.g. irradiation, alkylating agents such as cyclophosphamide, and anti-metabolites such as 5-Fluorouracil
- Other cancer therapies have used immunotherapies that selectively bind mutant tumor antigens on fast-growing cancer cells (e.g., monoclonal antibodies).
- tumors often recur following these therapies at the same or different site(s), indicating that not all cancer cells have been eradicated. Relapse may be due to insufficient chemotherapeutic dosage and/or emergence of cancer clones resistant to therapy.
- novel cancer treatment strategies are needed.
- hypoxia in the tumor microenvironment is a negative prognostic factor that ultimately promotes cancer progression, tumor recurrence, distant metastasis, and chemo- and radio-resistance. Hypoxia can induce stem cell characteristics in cancer cells. Increases in “stemness” may explain the clinical association of hypoxia with poor prognosis and drug-resistance. There remains a need to develop “hypoxia-specific” therapeutics to target hypoxic microenvironments.
- the present disclosure relates to methods of treating hypoxic cancer stem cells (CSCs) by administering a therapeutically effective amount of an anti-angiogenic agent and a therapeutically effective amount of a mitochondrial biogenesis inhibitor to a patient in need thereof.
- the anti-angiogenic agent includes at least one of bevacizumab, itraconazole, carboxyamidotriazole, TNP-470, CM101, INF-alpha, IL-12, platelet factor-4, suramin, SU5416, thrombospondin, a VEGFR antagonist, an angiostatic steroid plus heparin, Cartilage-Derived Angiogenesis Inhibitory Factor, a matrix metalloproteinase inhibitor, angiostatin, endostatin, 2-methoxyestradiol, tecogalan, tetrathiomolybdate, thalidomide, thrombospondin, prolactin, linomide, ⁇ V ⁇ 3 inhibitors,
- the mitochondrial biogenesis inhibitor includes at least one of a tetracycline, doxycycline, tigecycline, minocycline, eyrthromycin, azithromycin, clarithromycin, pyrvinium pamoate, atovaquone, bedaquiline, irinotecan, sorafenib, niclosamide, berberine, stiripentol, chloroquine, etomoxir, perhexiline, mitoriboscin, mitoketoscin, mitoflavoscin, TPP-compound, mDIVI1, caffeic acid phenyl ester, antimitoscin, and repurposcin.
- a tetracycline doxycycline
- tigecycline minocycline
- eyrthromycin azithromycin
- clarithromycin pyrvinium pamoate
- atovaquone bedaquiline
- irinotecan soraf
- the present disclosure also relates to methods of sensitizing hypoxic CSCs to one or more chemotherapies, the method including: administering a therapeutically effective amount of a mitochondrial biogenesis inhibitor with the chemotherapy to a patient in need thereof.
- the mitochondrial biogenesis inhibitor may include at least one of a tetracycline, doxycycline, tigecycline, minocycline, eyrthromycin, azithromycin, clarithromycin, pyrvinium pamoate, atovaquone, bedaquiline, irinotecan, sorafenib, niclosamide, berberine, stiripentol, chloroquine, etomoxir, perhexiline, mitoriboscin, mitoketoscin, mitoflavoscin, TPP-compound, mDIVI1, caffeic acid phenyl ester, antimitoscin, and repurposcin.
- the chemotherapy is
- the present disclosure also relates to methods of sensitizing hypoxic CSCs to radiotherapy.
- a therapeutically effective amount of a mitochondrial biogenesis inhibitor with radiotherapy may be administered to a patient in need thereof.
- the mitochondrial biogenesis inhibitor may include at least one of a tetracycline, doxycycline, tigecycline, minocycline, eyrthromycin, azithromycin, clarithromycin, pyrvinium pamoate, atovaquone, bedaquiline, irinotecan, sorafenib, niclosamide, berberine, stiripentol, chloroquine, etomoxir, perhexiline, mitoriboscin, mitoketoscin, mitoflavoscin, TPP-compound, mDIVI1, caffeic acid phenyl ester, antimitoscin, and repurposcin.
- FIG. 1 outlines an experimental approach to study the role of chronic hypoxia and oxidative stress in the propagation of breast cancer stem cells (CSCs).
- CSCs breast cancer stem cells
- FIG. 2A-F show the effects of chronic hypoxia mitochondrial mass of MCF7 cells over time.
- FIGS. 2G-H show the effects of chronic hypoxia on mitochondrial protein TOMM20 in MCF7 cells over time.
- FIGS. 3A-C show the effects of chronic hypoxia on mammosphere formation in MCF7 cells.
- FIGS. 4A-B show that doxycycline treatment inhibits hypoxia-induced mammosphere formation in MCF7 cells.
- FIGS. 5A-C show that a fraction of CSCs is resistant to Paclitaxel treatment (resistance measured by mammosphere formation), but that doxycycline treatment inhibits Paclitaxel-resistant CSC activity in MCF7 cells.
- FIGS. 6A-B show the effects of hypoxia on oxygen consumption rates (OCR) over time in MCF7 cells.
- FIGS. 7A-B show the effects of hypoxia on extracellular acidification rates (ECAR) over time in MCF7 cells.
- FIGS. 8A-B show the effects of hypoxia on aldehyde dehydrogenase (ALDH) activity in MCF7 cells.
- FIGS. 9A-D show the effects of chronic hypoxia on reactive oxygen species (ROS) production.
- FIG. 9E shows that Mito-TEMPO inhibits mammosphere formation in MCF7 cells treated with chronic hypoxia.
- FIGS. 10A-D show that H1F1-alpha expression is upregulated during acute hypoxia but not chronic hypoxia.
- FIGS. 11A-B show that treatment with valproic acid stimulates mitochondrial biogenesis and increases mammosphere formation in MCF7 cells.
- FIGS. 11C-D show that treatment with valproic acid increases ALDH activity.
- FIGS. 12A-C show that treatment with Etomoxir, Perhexiline, or glycolysis inhibitors inhibits basal and valproic acid-augmented CSC propagation, as measured by mammosphere formation.
- FIG. 13 outlines the means by which mitochondrial antioxidants such as Mito-Tempo and mitochondrial protein translation inhibitors such as doxycycline may be used to target hypoxic CSCs.
- FIG. 14 summarizes how valproic acid-induced increases in CSC propagation may be blocked using fatty acid beta-oxidation (FAO) inhibitors.
- FEO fatty acid beta-oxidation
- the mitochondrial ribosome is an untapped gateway for treating a number of afflictions, ranging from cancer to bacterial and fungal infections to aging. Functional mitochondria are required for the propagation of CSCs. Inhibiting mitochondrial biogenesis in CSCs impedes the propagation of those cells. Mitochondrial inhibitors therefore represent a new class of anti-cancer therapeutics. The inventors hypothesized that mitochondrial inhibitors could be further used to target hypoxic CSCs.
- MCF7 cells were obtained from ATCC and cultured in DMEM (Sigma Aldrich).
- DMEM Sigma Aldrich
- MCF7 cells were cultured in low glucose DMEM in a multi-gas N 2 /CO 2 hypoxic chamber at 1% O 2 .
- MCF7 cells were cultured in low glucose DMEM at 21% O 2 to serve as a normoxic control.
- MCF7 cell monolayers were subjected to hypoxia (1% oxygen) for increasing periods of time (0, 6, 24, 48, 72, and 96 hours).
- hypoxia 1% oxygen
- MCF7 cells were trypsinized and subjected to fluorescence-activated cell sorting (FACS) with MitoTracker Deep-Red-FM (Life Technologies).
- MitoTracker Deep Red localizes to mitochondria regardless of mitochondrial membrane potential.
- Cells were incubated with pre-warmed MitoTracker staining solution (diluted in PBS/CM to a final concentration of 10 nM) for 30-60 min at 37° C. All subsequent steps were performed in the dark.
- FIGS. 2A-C show that 6, 24, and 48 hours of hypoxia had no significant effect on mitochondrial mass.
- FIGS. 2D-E show that 72 and 96 hours of hypoxia treatment significantly increased mitochondrial mass.
- FIG. 2F is a representative FACS tracing showing 96 hours of hypoxia increased mitochondrial mass. The effects of hypoxia treatment were confirmed using immunoblot analysis with TOMM20, a marker of mitochondrial mass.
- FIG. 2G shows that 6 hours of hypoxia treatment has no effect on TOMM20 expression
- FIG. 2H shows that 96 hours of hypoxia treatment increases TOMM20 expression.
- a single cell suspension of MCF7 cells previously exposed to normoxia (21% O 2 ) or hypoxia (1% O 2 ) for 6 h, 72 h or 96 h was prepared using enzymatic (1 ⁇ Trypsin-EDTA, Sigma Aldrich) and manual disaggregation (25-gauge needle).
- FIG. 3A shows that acute hypoxia (6 hour treatment) inhibited mammosphere formation by more than 60%.
- FIGS. 3B-C show that chronic hypoxia (72 and 96 hour treatments) increased marnmosphere formation.
- FIGS. 4A-B show that doxycycline treatment inhibited hypoxia-induced mammosphere formation under normoxic and hypoxic conditions.
- hypoxic CSCs are known to be highly resistant to conventional chemotherapies such as Paclitaxel.
- FIGS. 5A-B show that a fraction of CSCs is resistant to Paclitaxel treatment, but that doxycycline treatment significantly inhibits Paclitaxel-resistant CSC activity ( FIG. 5C ).
- mitochondrial biogenesis inhibitors may be used as adjuvants to decrease CSC resistance to chemotherapies.
- Anti-angiogenic therapies have also emerged as promising anti-cancer agents, based on their ability to target tumor blood vessels and deprive the cells of essential nutrients.
- clinical and pre-clinical data have shown that long-term administration of anti-angiogenic agents can increase tumor invasiveness and metastasis.
- Failure of angiogenesis inhibitors may be due to their ability to generate intra-tumoral hypoxia, which stimulates CSCs survival and propagation.
- doxycycline with angiogenesis inhibitors such as bevacizumab (Avastin), itraconazole, carboxyamidotriazole, TNP-470 (analog of fumagillin), CM101, INF-alpha, IL-12, platelet factor-4, suramin, SU5416, thrombospondin, VEGFR antagonists, angiostatic steroids plus heparin, Cartilage-Derived Angiogenesis Inhibitory Factor, matrix metalloproteinase inhibitors, angiostatin, endostatin, 2-methoxyestradiol, tecogalan, tetrathiomolybdate, thalidomide, thrombospondin, prolactin, linomide, ⁇ v ⁇ 3 inhibitors, ramucirumab, tasquiniod, ranibizumab, sorafenib (Nexavar®), sunitinib (Sutent®), paz
- the present approach relates to methods of analyzing the effects of mitochondrial biogenesis inhibitors on the metabolic state of CSCs following chronic hypoxia treatment.
- extracellular acidification rates (ECAR) and real-time oxygen consumption rates (OCR) for MCF7 cells may be determined using the Seahorse Extracellular Flux (XFe-96) analyzer (Seahorse Bioscience). After exposure to normoxia (21% O 2 ) or hypoxia (1% O 2 ) for 96 hours, 15,000 MCF7 cells per well were seeded into XFe-96 well cell culture plates for 24 hours.
- XF assay media or for OCR measurement, XF assay media supplemented with 10 mM glucose, 1 mM Pyruvate, 2 mM L-glutamine and adjusted at 7.4 pH). Cells were then maintained in 175 ⁇ L/well of XF assay media at 37° C., in a non-CO 2 incubator for 1 hour.
- unbiased label-free proteomics analysis may be conducted to determine the effects of mitochondrial biogenesis inhibitors on the metabolic state of CSCs following chronic hypoxia treatment.
- Cell lysates were prepared for trypsin digestion by sequential reduction of disulphide bonds with TCEP and alkylation with MMTS. Then, the peptides were extracted and prepared for LC-MIS/MS. All LC-MS/MS analyses were performed on an LTQ Orbitrap XL mass spectrometer (Thermo Scientific, San Jose, Calif.) coupled to an Ultimate 3000 RSLC nano system (Thermo Scientific, formerly Dionex, The Netherlands).
- Xcalibur raw data files acquired on the LTQ-Orbitrap XL were directly imported into Progenesis LCMS software (Waters Corp., Milford, Mass., formerly Non-linear dynamics, Newcastle upon Tyne, UK) for peak detection and alignment. Data were analyzed using the Mascot search engine. Five technical replicates were analyzed for each sample type. Table 1 shows three mitochondrial ribosomal proteins (MRPL4, MRPS35 and MRPL47) were upregulated in response to chronic hypoxia. Eleven other proteins related to mitochondrial biogenesis were upregulated, including: HYOU1, YARS2, LONP1, POLRMT, COQ9, SARS2, HSPA9, HSPD1, ATP5J, and ATPAF1.
- LRPPRC mitophagy inhibitor that prevents the autophagic digestion of mitochondria
- HYOU1 hyperoxia up-regulated protein 1
- Table 1 also shows other up-regulated proteins that are part of the OXPHOS complexes, such as NDUFV2.
- the present approach further includes methods of analyzing the effects of hypoxia on CSCs by examining relative changes of CSC markers.
- aldehyde dehydrogenase (ALDH) activity is routinely used as a marker for CSCs. It should be appreciated by those in the art that other CSC markers may be used.
- ALDH activity was assessed by FACS analysis in MCF7 cells cultured for 72 hours in normoxia (21% O 2 ) or hypoxia (1% O 2 ).
- the ALDEFLUOR kit (StemCell Technologies) was used to isolate the population with high ALDH enzymatic activity by FACS (Fortessa, BD Bioscence).
- FIGS. 8A-B show that chronic hypoxia increased ALDH activity by more than 1.5-fold.
- the present approach also involves methods of determining whether oxidative stress promotes chronic hypoxia-associated increases in CSC activity.
- the inventors quantitatively measured reactive oxygen species (ROS) production following acute and chronic hypoxia.
- ROS production was measured by FACS analysis using CM-H2DCFDA (C6827, Life Technologies), a cell-permeable probe that is non-fluorescent until oxidation within the cell.
- MCF7 cells were cultured upon normoxia (21% O 2 ) or hypoxia (1% O 2 ) for 6 hours or 96 hours. Thereafter, cells were washed with PBS and incubated at 37° C. for 20 min with 1 ⁇ M CM-H2DCFDA diluted in PBS/CM. All subsequent steps were performed in the dark.
- FIGS. 9A-D show that chronic hypoxia induced a more than 1.5-fold increase in ROS production, whereas no increase in ROS production was observed after acute hypoxia.
- FIG. 9E demonstrates that 4-hydroxy-TEMPO and Mito-TEMPO effectively inhibited mammosphere formation by more than 70% at a concentration of 100 ⁇ M.
- Mito-TEMPO is a mitochondrially-targeted form of TEMPO, which contains a chemical mitochondrial targeting signal.
- mitochondrial oxidative stress may contribute to hypoxia-induced ‘stemness.’
- FIG. 13 summarized how doxycycline (used to target mitochondrial protein translation) and Mito-TEMPO (used as a mitochondrial antioxidant) may both be used to functionally target hypoxic CSCs.
- HIF1-alpha is a well-known transcriptional mediator of the acute effects of hypoxia, but its functional role in chronic hypoxia is less defined.
- the inventors examined the expression levels of HIF1-alpha and pERK-1/2 by immunoblot analysis. MCF7 cell protein lysates were electrophoresed through a reducing SDS/10% (w/v) polyacrylamide gel, electroblotted onto a nitrocellulose membrane and probed with primary antibodies against HIF1-alpha, phosphorylated ERK 1/2 (E-4), ERK2 (C-14), and ⁇ -actin (C2) (all purchased from Santa Cruz Biotechnology).
- FIG. 10 shows that HIF1-alpha was strongly upregulated during acute hypoxia but remains undetectable during chronic hypoxia. Conversely, the levels of activated phospho-ERK-1/2 were unchanged by acute hypoxia but were significantly elevated by chronic hypoxia. These two signaling molecules may contribute to metabolic signaling at different phases of the hypoxia-induced stress response. The activation of ERK-1/2 by chronic hypoxia may provide a key stimulus for enhancing anchorage-independent growth.
- the present approach also includes methods of investigating the role of fatty acid oxidation (FAO) in mitochondrial biogenesis and CSC propagation.
- FAO is the process by which fatty acids are catabolized in mitochondria and peroxisomes to generate Acetyl-CoA, which then may enter the TCA/Krebs cycle. In the process, the energy generated for each Acetyl-CoA molecule oxidized results in 1 GTP and 11 ATP molecules.
- the inventors used proteomics analysis to determine what metabolic enzymes related to mitochondrial FAO are upregulated during chronic hypoxia.
- Valproic acid an FDA-approved drug commonly used to treat epilepsy, on mitochondrial mass, mammosphere formation, and ALDH activity.
- Valproic acid is thought to behave as a fatty acid that stimulates FAO. It is chemically classified as a branched short-chain fatty acid.
- FIG. 11A shows that treatment with increasing concentrations of Valproic acid (0, 1, 2.5 and 5 mM) stimulates mitochondrial biogenesis, resulting in an up to 3-fold increase in mitochondrial mass. Valproic acid also increases mammosphere formation ( FIG. 11B ).
- FIGS. 11C-D 2.5 mM Valproic acid also increased ALDH activity by >1.5-fold, consistent with an increase in ‘stemness’.
- the inventors tested the effects of Etomoxir and Perhexiline, two inhibitors of FAO that target the enzyme CPT (carnitine O-palmitoyltransferase).
- FIG. 12A-B show that Etomoxir and Perhexiline inhibit basal and Valproic acid-augmented CSC propagation. Similar results were seen with Doxycycline treatment, which inhibits mitochondrial biogenesis ( FIG. 12A ).
- Glycolysis is required to provide additional TCA cycle intermediates for the mitochondrial processing of Acetyl-CoA.
- 2-deoxy-D-glucose (2-DG) or ascorbic acid were dissolved in culture medium.
- Treatment with glycolysis inhibitors (2-DG or Vitamin C (ascorbic acid)) was also sufficient to inhibit Valproic acid-augmented CSC propagation ( FIG. 12C ).
- the IC-50 for 2-DG was 1 mM, while the IC-50 for Vitamin C was ⁇ 0.5 mM.
- Vitamin C was two times as potent under Valproic acid-augmented conditions as compared to inventors' previously published results that investigated Vitamin C effects under basal conditions. Bonuccelli et al.
- Mitochondrial biogenesis inhibitors include tetracyclines (e.g., tetracycline, doxycycline, tigecycline, and minocycline); erythromycins (e.g., eyrthromycin, azithromycin, and clarithromycin); pyrvinium pamoate; atovaquone; bedaquiline; irinotecan; sorafenib; niclosamide; berberine; stiripentol; chloroquine; etomoxir; perhexiline, mitoriboscins, such as those disclosed in U.S.
- tetracyclines e.g., tetracycline, doxycycline, tigecycline, and minocycline
- erythromycins e.g., eyrthromycin, azithromycin, and clarithromycin
- pyrvinium pamoate atovaquone; bedaquiline; irinotecan; so
- a measurable value such as, for example, an amount or concentration and the like, is meant to encompass variations of 20%, ⁇ 10%, ⁇ 5%, ⁇ 1%, ⁇ 0.5%, or even ⁇ 0.1% of the specified amount.
- a range provided herein for a measurable value may include any other range and/or individual value therein.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This application claims the benefit of U.S. Provisional Patent Application No. 62/488,483, filed Apr. 21, 2017, the entirety of which is incorporated herein by reference.
- The present disclosure relates to methods of eradicating hypoxic cancer stem cells using inhibitors of mitochondrial biogenesis with anti-angiogenic therapies, and to methods of sensitizing hypoxic cancer cells to chemotherapies by treating the cells with one or more mitochondrial biogenesis inhibitors.
- Researchers have struggled to develop new anti-cancer treatments. Conventional cancer therapies (e.g. irradiation, alkylating agents such as cyclophosphamide, and anti-metabolites such as 5-Fluorouracil) have attempted to selectively detect and eradicate fast-growing cancer cells by interfering with cellular mechanisms involved in cell growth and DNA replication. Other cancer therapies have used immunotherapies that selectively bind mutant tumor antigens on fast-growing cancer cells (e.g., monoclonal antibodies). Unfortunately, tumors often recur following these therapies at the same or different site(s), indicating that not all cancer cells have been eradicated. Relapse may be due to insufficient chemotherapeutic dosage and/or emergence of cancer clones resistant to therapy. Hence, novel cancer treatment strategies are needed.
- Hypoxia in the tumor microenvironment is a negative prognostic factor that ultimately promotes cancer progression, tumor recurrence, distant metastasis, and chemo- and radio-resistance. Hypoxia can induce stem cell characteristics in cancer cells. Increases in “stemness” may explain the clinical association of hypoxia with poor prognosis and drug-resistance. There remains a need to develop “hypoxia-specific” therapeutics to target hypoxic microenvironments.
- The present disclosure relates to methods of treating hypoxic cancer stem cells (CSCs) by administering a therapeutically effective amount of an anti-angiogenic agent and a therapeutically effective amount of a mitochondrial biogenesis inhibitor to a patient in need thereof. In some embodiments, the anti-angiogenic agent includes at least one of bevacizumab, itraconazole, carboxyamidotriazole, TNP-470, CM101, INF-alpha, IL-12, platelet factor-4, suramin, SU5416, thrombospondin, a VEGFR antagonist, an angiostatic steroid plus heparin, Cartilage-Derived Angiogenesis Inhibitory Factor, a matrix metalloproteinase inhibitor, angiostatin, endostatin, 2-methoxyestradiol, tecogalan, tetrathiomolybdate, thalidomide, thrombospondin, prolactin, linomide, αVβ3 inhibitors, ramucirumab, tasquinimod, ranibizumab, sorafenib, sunitinib, pazopanib, and everolimus. In some embodiments, the mitochondrial biogenesis inhibitor includes at least one of a tetracycline, doxycycline, tigecycline, minocycline, eyrthromycin, azithromycin, clarithromycin, pyrvinium pamoate, atovaquone, bedaquiline, irinotecan, sorafenib, niclosamide, berberine, stiripentol, chloroquine, etomoxir, perhexiline, mitoriboscin, mitoketoscin, mitoflavoscin, TPP-compound, mDIVI1, caffeic acid phenyl ester, antimitoscin, and repurposcin.
- The present disclosure also relates to methods of sensitizing hypoxic CSCs to one or more chemotherapies, the method including: administering a therapeutically effective amount of a mitochondrial biogenesis inhibitor with the chemotherapy to a patient in need thereof. In some embodiments, the mitochondrial biogenesis inhibitor may include at least one of a tetracycline, doxycycline, tigecycline, minocycline, eyrthromycin, azithromycin, clarithromycin, pyrvinium pamoate, atovaquone, bedaquiline, irinotecan, sorafenib, niclosamide, berberine, stiripentol, chloroquine, etomoxir, perhexiline, mitoriboscin, mitoketoscin, mitoflavoscin, TPP-compound, mDIVI1, caffeic acid phenyl ester, antimitoscin, and repurposcin. In some embodiments, the chemotherapy is paclitaxel.
- The present disclosure also relates to methods of sensitizing hypoxic CSCs to radiotherapy. A therapeutically effective amount of a mitochondrial biogenesis inhibitor with radiotherapy may be administered to a patient in need thereof. In some embodiments, the mitochondrial biogenesis inhibitor may include at least one of a tetracycline, doxycycline, tigecycline, minocycline, eyrthromycin, azithromycin, clarithromycin, pyrvinium pamoate, atovaquone, bedaquiline, irinotecan, sorafenib, niclosamide, berberine, stiripentol, chloroquine, etomoxir, perhexiline, mitoriboscin, mitoketoscin, mitoflavoscin, TPP-compound, mDIVI1, caffeic acid phenyl ester, antimitoscin, and repurposcin.
-
FIG. 1 outlines an experimental approach to study the role of chronic hypoxia and oxidative stress in the propagation of breast cancer stem cells (CSCs). -
FIG. 2A-F show the effects of chronic hypoxia mitochondrial mass of MCF7 cells over time.FIGS. 2G-H show the effects of chronic hypoxia on mitochondrial protein TOMM20 in MCF7 cells over time. -
FIGS. 3A-C show the effects of chronic hypoxia on mammosphere formation in MCF7 cells. -
FIGS. 4A-B show that doxycycline treatment inhibits hypoxia-induced mammosphere formation in MCF7 cells. -
FIGS. 5A-C show that a fraction of CSCs is resistant to Paclitaxel treatment (resistance measured by mammosphere formation), but that doxycycline treatment inhibits Paclitaxel-resistant CSC activity in MCF7 cells. -
FIGS. 6A-B show the effects of hypoxia on oxygen consumption rates (OCR) over time in MCF7 cells. -
FIGS. 7A-B show the effects of hypoxia on extracellular acidification rates (ECAR) over time in MCF7 cells. -
FIGS. 8A-B show the effects of hypoxia on aldehyde dehydrogenase (ALDH) activity in MCF7 cells. -
FIGS. 9A-D show the effects of chronic hypoxia on reactive oxygen species (ROS) production.FIG. 9E shows that Mito-TEMPO inhibits mammosphere formation in MCF7 cells treated with chronic hypoxia. -
FIGS. 10A-D show that H1F1-alpha expression is upregulated during acute hypoxia but not chronic hypoxia. -
FIGS. 11A-B show that treatment with valproic acid stimulates mitochondrial biogenesis and increases mammosphere formation in MCF7 cells.FIGS. 11C-D show that treatment with valproic acid increases ALDH activity. -
FIGS. 12A-C show that treatment with Etomoxir, Perhexiline, or glycolysis inhibitors inhibits basal and valproic acid-augmented CSC propagation, as measured by mammosphere formation. -
FIG. 13 outlines the means by which mitochondrial antioxidants such as Mito-Tempo and mitochondrial protein translation inhibitors such as doxycycline may be used to target hypoxic CSCs. -
FIG. 14 summarizes how valproic acid-induced increases in CSC propagation may be blocked using fatty acid beta-oxidation (FAO) inhibitors. - The following description illustrates embodiments of the present approach in sufficient detail to enable practice of the present approach. Although the present approach is described with reference to these specific embodiments, it should be appreciated that the present approach can be embodied in different forms, and this description should not be construed as limiting any appended claims to the specific embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the present approach to those skilled in the art.
- The mitochondrial ribosome is an untapped gateway for treating a number of afflictions, ranging from cancer to bacterial and fungal infections to aging. Functional mitochondria are required for the propagation of CSCs. Inhibiting mitochondrial biogenesis in CSCs impedes the propagation of those cells. Mitochondrial inhibitors therefore represent a new class of anti-cancer therapeutics. The inventors hypothesized that mitochondrial inhibitors could be further used to target hypoxic CSCs.
- The inventors examined the effects of chronic hypoxia and oxidative stress on the propagation of breast CSCs using MCF7 cells as a model system. It should be appreciated that other model systems may be used. An outline of the experimental approach is shown in
FIG. 1 . Briefly, MCF7 cells were obtained from ATCC and cultured in DMEM (Sigma Aldrich). For hypoxic testing, MCF7 cells were cultured in low glucose DMEM in a multi-gas N2/CO2 hypoxic chamber at 1% O2. In parallel, MCF7 cells were cultured in low glucose DMEM at 21% O2 to serve as a normoxic control. MCF7 cell monolayers were subjected to hypoxia (1% oxygen) for increasing periods of time (0, 6, 24, 48, 72, and 96 hours). Next, the MCF7 cells were trypsinized and subjected to fluorescence-activated cell sorting (FACS) with MitoTracker Deep-Red-FM (Life Technologies). MitoTracker Deep Red localizes to mitochondria regardless of mitochondrial membrane potential. Cells were incubated with pre-warmed MitoTracker staining solution (diluted in PBS/CM to a final concentration of 10 nM) for 30-60 min at 37° C. All subsequent steps were performed in the dark. Cells were washed in PBS, harvested, re-suspended in 300 μL of PBS and then analyzed by flow cytometry (Fortessa, BD Bioscience). Data analysis was performed using FlowJo software (Tree star Inc.).FIGS. 2A-C show that 6, 24, and 48 hours of hypoxia had no significant effect on mitochondrial mass. In contrast,FIGS. 2D-E show that 72 and 96 hours of hypoxia treatment significantly increased mitochondrial mass.FIG. 2F is a representative FACS tracing showing 96 hours of hypoxia increased mitochondrial mass. The effects of hypoxia treatment were confirmed using immunoblot analysis with TOMM20, a marker of mitochondrial mass.FIG. 2G shows that 6 hours of hypoxia treatment has no effect on TOMM20 expression, whereasFIG. 2H shows that 96 hours of hypoxia treatment increases TOMM20 expression. - The effects of chronic hypoxia on CSC activity may be examined using mammosphere formation assays, though it should be appreciated by those of skill in the art that other assays may be used. Briefly, a single cell suspension of MCF7 cells previously exposed to normoxia (21% O2) or hypoxia (1% O2) for 6 h, 72 h or 96 h was prepared using enzymatic (1× Trypsin-EDTA, Sigma Aldrich) and manual disaggregation (25-gauge needle). Cells were plated at a density of 500 cells/cm2 in mammosphere medium (DMFM-F12/B27/20-ng/ml EGF/PenStrep) in nonadherent conditions, in culture dishes coated with (2-hydroxyethylmethacrylate) (poly-HEMA, Sigma), in the presence of treatments. Cells were grown for 5 days and maintained in a humidified incubator at 37° C. at an atmospheric pressure in 5% (v/v) carbon dioxide/air. After five days of culturing, spheres greater than 50 μm in diameter were counted using an eye piece graticule, and the percentage of cells plated which formed spheres was calculated. Mammosphere assays were performed in triplicate and repeated three times independently.
FIG. 3A shows that acute hypoxia (6 hour treatment) inhibited mammosphere formation by more than 60%.FIGS. 3B-C show that chronic hypoxia (72 and 96 hour treatments) increased marnmosphere formation. - To determine whether mitochondrial biogenesis is required for hypoxia-induced CSC propagation, the inventors studied the effects of a mitochondrial biogenesis inhibitor. The antibiotic doxycycline is known to inhibit mitochondrial biogenesis, but it should be appreciated by those having skill in the art that other mitochondrial biogenesis inhibitors may be used. The inventors tested the effects of doxycycline on hypoxia-induced mammosphere formation.
FIGS. 4A-B show that doxycycline treatment inhibited hypoxia-induced mammosphere formation under normoxic and hypoxic conditions. - Hypoxic CSCs are known to be highly resistant to conventional chemotherapies such as Paclitaxel. The inventors hypothesized that mitochondrial biogenesis inhibitors may be used to sensitize hypoxic CSCSs to conventional chemotherapies.
FIGS. 5A-B show that a fraction of CSCs is resistant to Paclitaxel treatment, but that doxycycline treatment significantly inhibits Paclitaxel-resistant CSC activity (FIG. 5C ). Thus, mitochondrial biogenesis inhibitors may be used as adjuvants to decrease CSC resistance to chemotherapies. - Anti-angiogenic therapies have also emerged as promising anti-cancer agents, based on their ability to target tumor blood vessels and deprive the cells of essential nutrients. However, clinical and pre-clinical data have shown that long-term administration of anti-angiogenic agents can increase tumor invasiveness and metastasis. Failure of angiogenesis inhibitors may be due to their ability to generate intra-tumoral hypoxia, which stimulates CSCs survival and propagation. The combined use of doxycycline with angiogenesis inhibitors, such as bevacizumab (Avastin), itraconazole, carboxyamidotriazole, TNP-470 (analog of fumagillin), CM101, INF-alpha, IL-12, platelet factor-4, suramin, SU5416, thrombospondin, VEGFR antagonists, angiostatic steroids plus heparin, Cartilage-Derived Angiogenesis Inhibitory Factor, matrix metalloproteinase inhibitors, angiostatin, endostatin, 2-methoxyestradiol, tecogalan, tetrathiomolybdate, thalidomide, thrombospondin, prolactin, linomide, αvβ3 inhibitors, ramucirumab, tasquiniod, ranibizumab, sorafenib (Nexavar®), sunitinib (Sutent®), pazopanib (Votrient®), and everolimus (Afinitor®) may effectively block both blood vessel formation and CSC propagation and make anti-angiogenic therapy more effective.
- The present approach relates to methods of analyzing the effects of mitochondrial biogenesis inhibitors on the metabolic state of CSCs following chronic hypoxia treatment. For example, extracellular acidification rates (ECAR) and real-time oxygen consumption rates (OCR) for MCF7 cells may be determined using the Seahorse Extracellular Flux (XFe-96) analyzer (Seahorse Bioscience). After exposure to normoxia (21% O2) or hypoxia (1% O2) for 96 hours, 15,000 MCF7 cells per well were seeded into XFe-96 well cell culture plates for 24 hours. Then, cells were washed in pre-warmed XF assay media (or for OCR measurement, XF assay media supplemented with 10 mM glucose, 1 mM Pyruvate, 2 mM L-glutamine and adjusted at 7.4 pH). Cells were then maintained in 175 μL/well of XF assay media at 37° C., in a non-CO2 incubator for 1 hour. During the incubation time, 5 μL of 80 mM glucose, 9 μM oligomycin, and 1 M 2-deoxyglucose (for ECAR measurement) or 10 μM oligomycin, 9 μM FCCP, 10 μM Rotenone, 10 μM antimycin A (for OCR measurement), were loaded in XF assay media into the injection ports in the XFe-96 sensor cartridge. The data set was analyzed by XFe-96 software after the measurements were normalized by protein content (SRB). All experiments were performed three times independently
FIGS. 6A-B show that chronic hypoxia decreased OCR. Similarly, glycolysis rates, as measured by ECAR, were reduced by more than 60% (FIG. 7A-B ). - To further validate the functional observations from metabolic flux analysis, unbiased label-free proteomics analysis may be conducted to determine the effects of mitochondrial biogenesis inhibitors on the metabolic state of CSCs following chronic hypoxia treatment. Cell lysates were prepared for trypsin digestion by sequential reduction of disulphide bonds with TCEP and alkylation with MMTS. Then, the peptides were extracted and prepared for LC-MIS/MS. All LC-MS/MS analyses were performed on an LTQ Orbitrap XL mass spectrometer (Thermo Scientific, San Jose, Calif.) coupled to an Ultimate 3000 RSLC nano system (Thermo Scientific, formerly Dionex, The Netherlands). Xcalibur raw data files acquired on the LTQ-Orbitrap XL were directly imported into Progenesis LCMS software (Waters Corp., Milford, Mass., formerly Non-linear dynamics, Newcastle upon Tyne, UK) for peak detection and alignment. Data were analyzed using the Mascot search engine. Five technical replicates were analyzed for each sample type. Table 1 shows three mitochondrial ribosomal proteins (MRPL4, MRPS35 and MRPL47) were upregulated in response to chronic hypoxia. Eleven other proteins related to mitochondrial biogenesis were upregulated, including: HYOU1, YARS2, LONP1, POLRMT, COQ9, SARS2, HSPA9, HSPD1, ATP5J, and ATPAF1. Also, LRPPRC, a mitophagy inhibitor that prevents the autophagic digestion of mitochondria, was up-regulated. HYOU1 (hypoxia up-regulated protein 1), a mitochondrial chaperone protein that belongs to the
heat shock protein 70 family and that is involved in mitochondrial protein folding and confers cyto-protection under hypoxic conditions, was overexpressed by more than 170-fold. Table 1 also shows other up-regulated proteins that are part of the OXPHOS complexes, such as NDUFV2. -
TABLE 1 Mitochondrial Proteins Upregulated During Chronic Hypoxia (96 hours) in MCF7 Cells. Symbol Description Fold-Change (Up-regulation) HYOU1 Hypoxia up-regulated protein 1 173.99 DIABLO Diablo homolog, mitochondrial 51.91 ECSIT Evolutionarily conserved signaling intermediate in Toll pathway, mitochondrial 32.26 MRPL4 39S ribosomal protein L4, mitochondrial 10.62 PDK1 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial 8.39 HIBADH 3-hydroxyisobutyrate dehydrogenase, mitochondrial 8.28 YARS2 Tyrosine--tRNA ligase, mitochondrial 7.58 AK4 Adenylate kinase 4, mitochondrial 7.07 NDUFV2 NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial 6.94 ALDH6A1 Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial 6.17 MICU1 Calcium uptake protein 1, mitochondrial 5.1 LONP1 Lon protease homolog, mitochondrial 4.36 ACADSB Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial 4.25 MAVS Mitochondrial antiviral-signaling protein 4.12 SLC25A1 Mitochondrial 2-oxoglutarate/malate carrier protein 3.39 LRPPRC Leucine-rich PPR motif-containing protein, mitochondrial 2.92 MTHFD2 Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial 2.63 MRPS35 28S ribosomal protein S35, mitochondrial 2.58 ACAD9 Acyl-CoA dehydrogenase family member 9, mitochondrial 2.33 ABAT 4-aminobutyrate aminotransferase, mitochondrial 2.28 SLC25A1 Calcium-binding mitochondrial carrier protein Aralar2 2.21 ACADVL Very long-chain specific acyl-CoA dehydrogenase, mitochondrial 2.21 POLRM┐ DNA-directed RNA polymerase, mitochondrial 2.18 HADH Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial 2.17 COQ9 Ubiquinone biosynthesis protein COQ9, mitochondrial 2.12 SARS2 Serine--tRNAligase, mitochondrial 2.12 HSPA9 Stress-70 protein, mitochondrial 2.08 CS Citrate synthase, mitochondrial 2.08 PCCB Propionyl-CoA carboxylase beta chain, mitochondrial 2.05 HSPD1 60 kDa heat shock protein, mitochondrial 2.01 DECR1 2,4-dienoyl-CoA reductase, mitochondrial 2.01 ACOT9 Acyl-coenzyme A thioesterase 9, mitochondrial 1.97 GLS Glutaminase kidney isoform, mitochondrial 1.97 ACADM Medium-chain specific acyl-CoA dehydrogenase, mitochondrial 1.95 ATP5J ATP synthase-coupling factor 6, mitochondrial 1.93 ACSM2B Acyl-coenzyme A synthetase ACSM2B, mitochondrial 1.86 MMAB Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial 1.86 CPOX Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial 1.86 SUCLG2 Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial 1.84 MRPL47 39S ribosomal protein L47, mitochondrial 1.84 CPT2 Carnitine O-palmitoyltransferase 2, mitochondrial 1.79 IDH3B Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial 1.76 SLC25A2 Calcium-binding mitochondrial carrier protein SCaMC-1 1.74 ATPAF1 ATP synthase mitochondrial F1 complex assembly factor 1 1.74 NNT NAD(P) transhydrogenase, mitochondrial 1.73 - The present approach further includes methods of analyzing the effects of hypoxia on CSCs by examining relative changes of CSC markers. For example, aldehyde dehydrogenase (ALDH) activity is routinely used as a marker for CSCs. It should be appreciated by those in the art that other CSC markers may be used. ALDH activity was assessed by FACS analysis in MCF7 cells cultured for 72 hours in normoxia (21% O2) or hypoxia (1% O2). The ALDEFLUOR kit (StemCell Technologies) was used to isolate the population with high ALDH enzymatic activity by FACS (Fortessa, BD Bioscence). Briefly, 1×105 MCF7 cells were incubated in 1 ml ALDEFLUOR assay buffer containing ALDH substrate (5 μl/ml) for 40 minutes at 37° C. In each experiment, a sample of cells was stained under identical conditions with 30 μM of diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor, as a negative control. The ALDEFLUOR-positive population was established in according to the manufacturer's instructions and was evaluated in 3×104 cells. Data analysis was performed using FlowJo software (Tree star Inc.),
FIGS. 8A-B show that chronic hypoxia increased ALDH activity by more than 1.5-fold. - The present approach also involves methods of determining whether oxidative stress promotes chronic hypoxia-associated increases in CSC activity. The inventors quantitatively measured reactive oxygen species (ROS) production following acute and chronic hypoxia. ROS production was measured by FACS analysis using CM-H2DCFDA (C6827, Life Technologies), a cell-permeable probe that is non-fluorescent until oxidation within the cell. MCF7 cells were cultured upon normoxia (21% O2) or hypoxia (1% O2) for 6 hours or 96 hours. Thereafter, cells were washed with PBS and incubated at 37° C. for 20 min with 1 μM CM-H2DCFDA diluted in PBS/CM. All subsequent steps were performed in the dark. Cells were rinsed, harvested, re-suspended in PBS/CM and then analyzed by flow cytometry (Fortessa, BD Bioscience). ROS levels were estimated by using the mean fluorescent intensity of the viable cell population. The results were analyzed using FlowJo software (Tree star Inc.).
FIGS. 9A-D show that chronic hypoxia induced a more than 1.5-fold increase in ROS production, whereas no increase in ROS production was observed after acute hypoxia. - To determine if oxidative stress drives the observed hypoxia-induced increase in ‘stemness’, the inventors determined whether simple antioxidants can inhibit mammosphere formation. For example, inventors used TEMPO-derivatives that behave as membrane-permeable sodium oxide dismutase (SOD)-mimetic agents to scavenge superoxide anions and other free radicals.
FIG. 9E demonstrates that 4-hydroxy-TEMPO and Mito-TEMPO effectively inhibited mammosphere formation by more than 70% at a concentration of 100 μM. Mito-TEMPO is a mitochondrially-targeted form of TEMPO, which contains a chemical mitochondrial targeting signal. Thus, mitochondrial oxidative stress may contribute to hypoxia-induced ‘stemness.’FIG. 13 summarized how doxycycline (used to target mitochondrial protein translation) and Mito-TEMPO (used as a mitochondrial antioxidant) may both be used to functionally target hypoxic CSCs. - The present approach further involves methods of determining what signaling cascades may be implicated during chronic hypoxia. For example, HIF1-alpha is a well-known transcriptional mediator of the acute effects of hypoxia, but its functional role in chronic hypoxia is less defined. The inventors examined the expression levels of HIF1-alpha and pERK-1/2 by immunoblot analysis. MCF7 cell protein lysates were electrophoresed through a reducing SDS/10% (w/v) polyacrylamide gel, electroblotted onto a nitrocellulose membrane and probed with primary antibodies against HIF1-alpha,
phosphorylated ERK 1/2 (E-4), ERK2 (C-14), and β-actin (C2) (all purchased from Santa Cruz Biotechnology). Proteins were detected by horseradish peroxidase-linked secondary antibodies and revealed using the SuperSignal west pico chemiluminescent substrate (Fisher Scientific).FIG. 10 shows that HIF1-alpha was strongly upregulated during acute hypoxia but remains undetectable during chronic hypoxia. Conversely, the levels of activated phospho-ERK-1/2 were unchanged by acute hypoxia but were significantly elevated by chronic hypoxia. These two signaling molecules may contribute to metabolic signaling at different phases of the hypoxia-induced stress response. The activation of ERK-1/2 by chronic hypoxia may provide a key stimulus for enhancing anchorage-independent growth. - The present approach also includes methods of investigating the role of fatty acid oxidation (FAO) in mitochondrial biogenesis and CSC propagation. FAO is the process by which fatty acids are catabolized in mitochondria and peroxisomes to generate Acetyl-CoA, which then may enter the TCA/Krebs cycle. In the process, the energy generated for each Acetyl-CoA molecule oxidized results in 1 GTP and 11 ATP molecules. The inventors used proteomics analysis to determine what metabolic enzymes related to mitochondrial FAO are upregulated during chronic hypoxia. The inventors found that twelve mitochondrial proteins involved in FAO were induced by chronic hypoxia, including HIBADH, ACADSB, ACAD9, ACADVL, HADH, PCCB, DECR1, ACOT9, ACADM, ACSM2B, SUCLG2 and CPT2. These results are shown in Table 2.
-
TABLE 2 Mitochondrial Proteins Involved in Fatty Acid Oxidation Upregulated during Chronic Hypoxia. Symbol Description Fold-Change (Up-regulation) HIBADH 3-hydroxyisobutyrate dehydrogenase, mitochondrial 8.28 ACADSB Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial 4.25 ACAD9 Acyl-CoA dehydrogenase family member 9, mitochondrial2.33 ACADVL Very long-chain specific acyl-CoA dehydrogenase, mitochondrial 2.21 HADH Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial 2.17 PCCB Propionyl-CoA carboxylase beta chain, mitochondrial 2.05 DECR1 2,4-dienoyl-CoA reductase, mitochondrial 2.01 ACOT9 Acyl- coenzyme A thioesterase 9, mitochondrial1.97 ACADM Medium-chain specific acyl-CoA dehydrogenase, mitochondrial 1.95 ACSM2B Acyl-coenzyme A synthetase ACSM2B, mitochondrial 1.86 SUCLG2 Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial 1.84 CPT2 Carnitine O- palmitoyltransferase 2, mitochondrial1.79 - To further analyze the role of FAO in biogenesis and CSC propagation, inventors tested the effects of Valproic acid, an FDA-approved drug commonly used to treat epilepsy, on mitochondrial mass, mammosphere formation, and ALDH activity. Valproic acid is thought to behave as a fatty acid that stimulates FAO. It is chemically classified as a branched short-chain fatty acid.
FIG. 11A shows that treatment with increasing concentrations of Valproic acid (0, 1, 2.5 and 5 mM) stimulates mitochondrial biogenesis, resulting in an up to 3-fold increase in mitochondrial mass. Valproic acid also increases mammosphere formation (FIG. 11B ). 2.5 mM Valproic acid also increased ALDH activity by >1.5-fold, consistent with an increase in ‘stemness’ (FIGS. 11C-D ). To validate that Valproic acid increases CSC propagation by a metabolic mechanism, the inventors tested the effects of Etomoxir and Perhexiline, two inhibitors of FAO that target the enzyme CPT (carnitine O-palmitoyltransferase).FIG. 12A-B show that Etomoxir and Perhexiline inhibit basal and Valproic acid-augmented CSC propagation. Similar results were seen with Doxycycline treatment, which inhibits mitochondrial biogenesis (FIG. 12A ). - Glycolysis is required to provide additional TCA cycle intermediates for the mitochondrial processing of Acetyl-CoA. The inventors hypothesized that inhibition of glycolysis will inhibit CSC formation. Briefly, 2-deoxy-D-glucose (2-DG) or ascorbic acid were dissolved in culture medium. Treatment with glycolysis inhibitors (2-DG or Vitamin C (ascorbic acid)) was also sufficient to inhibit Valproic acid-augmented CSC propagation (
FIG. 12C ). The IC-50 for 2-DG was 1 mM, while the IC-50 for Vitamin C was ˜0.5 mM. Vitamin C was two times as potent under Valproic acid-augmented conditions as compared to inventors' previously published results that investigated Vitamin C effects under basal conditions. Bonuccelli et al. Oncotarget, 8: 20667-20678 (2017). It should be appreciated that other metabolic agentslmitochondrial biogenesis inhibitors may be used in combination with anti-angiogenic agents to target CSCs. Mitochondrial biogenesis inhibitors include tetracyclines (e.g., tetracycline, doxycycline, tigecycline, and minocycline); erythromycins (e.g., eyrthromycin, azithromycin, and clarithromycin); pyrvinium pamoate; atovaquone; bedaquiline; irinotecan; sorafenib; niclosamide; berberine; stiripentol; chloroquine; etomoxir; perhexiline, mitoriboscins, such as those disclosed in U.S. Provisional Patent Application No. 62/471,688, filed Mar. 15, 2017, and Patent Cooperation Treaty (PCT) Patent Application PCT/US2018/022403, filed Mar. 14, 2018, the entireties of which are incorporated herein by reference; mitoketoscins, such as those disclosed in U.S. Provisional Patent Application No. 62/524,829, filed Jun. 26, 2017, the entirety of which is incorporated herein by reference; mitoilavoscins, such as those disclosed in U.S. Provisional Patent Application No. 62/576,287, filed Oct. 24, 2017, the entirety of which is incorporated herein by reference; TPP-compounds (e.g., 2-butene-1,4-bis-TPP), such as those disclosed in U.S. Provisional Patent Application No. 62/590,432, filed Nov. 24, 2017, the entirety of which is incorporated herein by reference; mDIVI1, such as those disclosed in U.S. Provisional. Patent. Application No. 62/608,065, filed Dec. 20, 2017, the entirety of which is incorporated herein by reference; CAPE (caffeic acid phenyl ester); antimitoscins, such as those disclosed in 62/508,702, filed May 19, 2017, the entirety of which is incorporated herein by reference; repurposcins such as those disclosed in U.S. Provisional Patent Application No. 62/593,372, filed Dec. 1, 2017, the entirety of which is incorporated herein by reference; other known mitochondrial inhibitors. Table 3 provides a list of metabolic agents and their respective IC-50s for inhibiting CSC propagation. -
TABLE 3 Metabolic Agents and Respective IC-50s. DRUG IC-50 Doxycycline 5 mM Azithromycin 50-100 1 mM Pyrvinium pamoate 100 nM Atovaquone 1 mM Bedaquiline 1 mM Irinotecan 500 nM Sorafenib 0.5 to 1 mM Niclosamide 100 nM Berberine 1 mM 2-DG (2-deoxy-glucose) 10-20 mM Vitamin C (ascorbic acid) 1 mM Stiripentol 10-50 mM Chloroquine <25 mM Etomoxir <200 mM Perhexiline <100 nM Mitoriboscins <5 mM; 500 nM for ATP Mitoketoscins <10 mM Mitoflavoscins 3 nM TPP-compounds (e.g., 2-butene-1,4-bis-TPP) 500 nM mDIVI1 10 mM CAPE (caffeic acid phenyl ester) 1 mM - The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used in the description of the invention and the appended claims, the singular forms “a,” “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. The invention includes numerous alternatives, modifications, and equivalents as will become apparent from consideration of the following detailed description.
- It will be understood that although the terms “first,” “second,” “third,” “a),” “b),” and “c),” etc. may be used herein to describe various elements of the invention should not be limited by these terms. These terms are only used to distinguish one element of the invention from another. Thus, a first element discussed below could be termed a element aspect, and similarly, a third without departing from the teachings of the present invention. Thus, the terms “first,” “second,” “third,” “a),” “b),” and “c),” etc. are not intended to necessarily convey a sequence or other hierarchy to the associated elements but are used for identification purposes only. The sequence of operations (or steps) is not limited to the order presented in the claims.
- Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the present application and relevant art and should not be interpreted in an idealized or overly formal sense unless expressly so defined herein. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. In case of a conflict in terminology, the present specification is controlling.
- Also as used herein, “and/or” refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative (“or”).
- Unless the context indicates otherwise, it is specifically intended that the various features of the invention described herein can be used in any combination. Moreover, the present invention also contemplates that in some embodiments of the invention, any feature or combination of features set forth herein can be excluded or omitted. To illustrate, if the specification states that a complex comprises components A, B and C, it is specifically intended that any of A, B or C, or a combination thereof, can be omitted and disclaimed.
- As used herein, the transitional phrase “consisting essentially of” (and grammatical variants) is to be interpreted as encompassing the recited materials or steps “and those that do not materially affect the basic and novel characteristic(s)” of the claimed invention. Thus, the term consisting essentially of” as used herein should not be interpreted as equivalent to “comprising.”
- The term “about,” as used herein when referring to a measurable value, such as, for example, an amount or concentration and the like, is meant to encompass variations of 20%, ±10%, ±5%, ±1%, ±0.5%, or even ±0.1% of the specified amount. A range provided herein for a measurable value may include any other range and/or individual value therein.
- Having thus described certain embodiments of the present invention, it is to be understood that the invention defined by the appended claims is not to be limited by particular details set forth in the above description as many apparent variations thereof are possible without departing from the spirit or scope thereof as hereinafter claimed.
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/549,475 US20220096502A1 (en) | 2017-04-21 | 2021-12-13 | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762488483P | 2017-04-21 | 2017-04-21 | |
PCT/US2018/028601 WO2018195446A1 (en) | 2017-04-21 | 2018-04-20 | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
US201916606849A | 2019-10-21 | 2019-10-21 | |
US17/549,475 US20220096502A1 (en) | 2017-04-21 | 2021-12-13 | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/606,849 Continuation US11229657B2 (en) | 2017-04-21 | 2018-04-20 | Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy |
PCT/US2018/028601 Continuation WO2018195446A1 (en) | 2017-04-21 | 2018-04-20 | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220096502A1 true US20220096502A1 (en) | 2022-03-31 |
Family
ID=63856149
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/606,849 Active 2038-07-17 US11229657B2 (en) | 2017-04-21 | 2018-04-20 | Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy |
US17/549,475 Pending US20220096502A1 (en) | 2017-04-21 | 2021-12-13 | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/606,849 Active 2038-07-17 US11229657B2 (en) | 2017-04-21 | 2018-04-20 | Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy |
Country Status (4)
Country | Link |
---|---|
US (2) | US11229657B2 (en) |
EP (1) | EP3612177A4 (en) |
CA (1) | CA3060509A1 (en) |
WO (1) | WO2018195446A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3060510A1 (en) | 2017-04-21 | 2018-10-25 | Lunella Biotech, Inc. | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
EP3612177A4 (en) * | 2017-04-21 | 2021-01-13 | Lunella Biotech, Inc. | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
MX2019013735A (en) | 2017-05-19 | 2020-01-15 | Lunella Biotech Inc | Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells. |
EP3624897A4 (en) | 2017-05-19 | 2021-07-14 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
US11667639B2 (en) | 2017-06-26 | 2023-06-06 | Lunella Biotech, Inc. | Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells |
CN111053900B (en) * | 2019-11-19 | 2022-05-03 | 南京大学射阳高新技术研究院 | Platelet drug-loading system for targeting tumor and improving radiotherapy sensitivity and preparation method thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070191935A1 (en) * | 2006-02-06 | 2007-08-16 | Conor Medsystems, Inc. | Drug Delivery Stent with Extended In Vivo Drug Release |
US20120258937A1 (en) * | 2011-04-08 | 2012-10-11 | Fox Chase Cancer Center | Targeting Estrogen Receptors in the Treatment of Lymphangioleiomyomatosis |
WO2014029016A1 (en) * | 2012-08-24 | 2014-02-27 | University Health Network | Compositions comprising a glycylcycline and a tyrosine kinase inhibitor for treating cancer |
US20150335609A1 (en) * | 2012-02-17 | 2015-11-26 | Pharmacyclics, Inc. | Combinations of histone deacetylase inhibitor and pazopanib and uses thereof |
US20160228399A1 (en) * | 2013-11-01 | 2016-08-11 | Pitney Pharmaceuticals Pty Limited | Pharmaceutical combinations for the treatment of cancer |
US11229657B2 (en) * | 2017-04-21 | 2022-01-25 | Lunella Biotech, Inc. | Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3517067A (en) | 1964-02-11 | 1970-06-23 | Eastman Kodak Co | Syntheses of quaternary phosphonium salts |
EP0310361A3 (en) | 1987-09-30 | 1989-05-24 | Beckman Instruments, Inc. | Tridentate conjugate and method of use thereof |
SI9011409A (en) | 1990-07-18 | 1995-10-31 | Pliva Pharm & Chem Works | O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them |
EP0656422B1 (en) | 1993-11-05 | 2000-04-26 | Amersham Pharmacia Biotech UK Limited | Chloramphenicol acetyl transferase (CAT) assay |
WO1995015770A1 (en) | 1993-12-09 | 1995-06-15 | Neorx Corporation | Pretargeting methods and compounds |
US5441939A (en) | 1994-03-04 | 1995-08-15 | Pfizer Inc. | 3"-desmethoxy derivatives of erythromycin and azithromycin |
KR970702725A (en) | 1994-04-26 | 1997-06-10 | 노부히로 나리따 | Medical Composition as a Remedy for Nonsmall Cell Lung Cancer |
JPH11504916A (en) | 1995-05-03 | 1999-05-11 | ファイザー・インコーポレーテッド | New tetracycline derivatives |
US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
US5837696A (en) | 1997-01-15 | 1998-11-17 | The Research Foundation Of State University Of New York | Method of inhibiting cancer growth |
NZ505352A (en) | 1997-11-25 | 2002-12-20 | Univ Otago | Mitochondrially targeted antioxidants |
EP0941998B1 (en) | 1998-03-03 | 2004-09-01 | Pfizer Products Inc. | 3,6-ketal macrolide antibiotics |
AUPP437698A0 (en) | 1998-06-30 | 1998-07-23 | Baumgart, Karl | Methods for treatment of coronary, carotid and other vascular disease |
US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US7485298B2 (en) | 2002-05-23 | 2009-02-03 | Michael Powell | Diagnosis and treatment of human dormancy-related sequellae |
NZ541846A (en) | 2003-01-27 | 2008-12-24 | Endocyte Inc | Vitamin receptor binding drug delivery conjugates |
WO2005062851A2 (en) | 2003-12-22 | 2005-07-14 | Pappolla Miguel A | Indole-3-propionamide and derivatives thereof |
JP2005200419A (en) | 2004-01-16 | 2005-07-28 | National Health Research Inst | Method for treating cancer |
US20050256081A1 (en) | 2004-02-26 | 2005-11-17 | Peyman Gholam A | Tetracycline derivatives for the treatment of ocular pathologies |
US20060083727A1 (en) | 2004-07-15 | 2006-04-20 | Nanobac Pharmaceuticals, Inc. | Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation |
TW200616604A (en) | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
EP1836212B1 (en) | 2005-01-14 | 2011-09-07 | Glaxo Group Limited | Macrolide compounds containing biotin and photo-affinity group for macrolide target identification |
SG164368A1 (en) | 2005-07-18 | 2010-09-29 | Bipar Sciences Inc | Treatment of cancer |
MX2008014953A (en) * | 2006-05-26 | 2009-03-05 | Bayer Healthcare Llc | Drug combinations with substituted diaryl ureas for the treatment of cancer. |
WO2007143212A1 (en) | 2006-06-02 | 2007-12-13 | Ariad Gene Therapeutics, Inc. | Capecitabine combination therapy |
EP2074211B1 (en) | 2006-09-06 | 2013-03-13 | Medical Research Council | DNA polymerases incorporating dye-labelled nucleotide analogues |
JP2010508022A (en) | 2006-10-30 | 2010-03-18 | サザン リサーチ インスティチュート | Targeting NBS1-ATM to sensitize cancer cells to radiation therapy and chemotherapy |
ES2700074T3 (en) | 2006-12-14 | 2019-02-13 | Abraxis Bioscience Llc | Therapy for breast cancer based on the status of the hormone receptors with nanoparticles that comprise taxane |
US8075902B2 (en) | 2007-01-03 | 2011-12-13 | Michael Powell | Diagnosis and treatment of cancer related to human dormancy |
DE102007025423A1 (en) | 2007-05-30 | 2008-12-04 | Friedrich-Schiller-Universität Jena | Triphenylphosphonium derivatives for the targeted transport and release of substances into mitochondria and methods for their use |
US8647673B2 (en) | 2007-07-24 | 2014-02-11 | Wayne State University | Nanoparticles for imaging and treating chlamydial infection |
WO2009036108A1 (en) * | 2007-09-13 | 2009-03-19 | Children's Medical Center Corporation | Methods and compositions for inhibiting vascular leakage |
WO2009038656A1 (en) | 2007-09-17 | 2009-03-26 | Kosta Steliou | Mitochondria-targeting antioxidant therapeutics |
WO2009045443A2 (en) | 2007-10-02 | 2009-04-09 | The University Of Rochester | Methods and compositions related to synergistic responses to oncogenic mutations |
BRPI1014978A2 (en) | 2009-04-17 | 2019-07-02 | Colby Pharmaceutical Company | cancer treatment method and pharmaceutical composition. |
KR20120080579A (en) | 2009-08-25 | 2012-07-17 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Use of metformin in cancer treatment and prevention |
CN109224064A (en) | 2009-12-04 | 2019-01-18 | 昂科免疫有限公司 | The purposes of hypoxia inducible factor inhibitor |
US20120141467A1 (en) | 2010-12-03 | 2012-06-07 | Schneider Daniel J | Ascorbic acid to treat chronic obstructive lung diseases and non-Hodgkin's lymphoma |
AU2012272804B2 (en) | 2011-06-22 | 2017-07-06 | Vyome Therapeutics Limited | Conjugate-based antifungal and antibacterial prodrugs |
WO2013007708A1 (en) * | 2011-07-08 | 2013-01-17 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for treatment of liver cancer |
WO2013019975A1 (en) | 2011-08-03 | 2013-02-07 | University Of Iowa Research Foundation | Compositions and methods of treating cancer |
US9180134B2 (en) | 2011-08-18 | 2015-11-10 | Ecole Polytechnique Federale De Lausanne (Epel) | Mitochondrial ribosomal proteins as aging regulators |
WO2013040206A1 (en) | 2011-09-14 | 2013-03-21 | Lewis Thomas J | Novel formulations comprising macrolide and tetracycline and their uses |
CA2866080C (en) | 2012-03-01 | 2021-01-19 | University Of Cincinnati | Ros-activated compounds as selective anti-cancer therapeutics |
WO2014036037A1 (en) | 2012-08-28 | 2014-03-06 | Annam Biosciences, Llc | N-boc-dendrimers and their conjugates |
WO2014036654A1 (en) | 2012-09-06 | 2014-03-13 | Mcmaster University | Compounds and methods for selectively targeting cancer stem cells |
US20140106004A1 (en) | 2012-10-12 | 2014-04-17 | Bing Lou Wong | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
US9636329B2 (en) | 2012-11-06 | 2017-05-02 | Northwestern University | Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors |
WO2014108571A2 (en) | 2013-01-14 | 2014-07-17 | Biocopea Limited | Cancer drug and uses |
WO2014138338A1 (en) | 2013-03-06 | 2014-09-12 | The General Hospital Corporation | Combinatorial compositions and methods for treatment of melanoma |
EA029881B1 (en) | 2013-04-24 | 2018-05-31 | Смарт Брейн С.Р.О. | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level |
EP3016715A4 (en) | 2013-07-01 | 2017-02-08 | University Of Georgia Research Foundation, Inc. | Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy |
CA2843943A1 (en) | 2014-02-20 | 2014-05-28 | Pankaj Modi | Oral formulations of chemotherapeutic agents |
US10398663B2 (en) | 2014-03-14 | 2019-09-03 | University Of Georgia Research Foundation, Inc. | Mitochondrial delivery of 3-bromopyruvate |
EP3154596A4 (en) | 2014-06-10 | 2018-01-24 | Institute for Myeloma & Bone Cancer Research | Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid |
GB201414806D0 (en) | 2014-08-20 | 2014-10-01 | Ucl Business Plc | Cyclosporin conjugates |
US10413558B2 (en) | 2014-10-17 | 2019-09-17 | Targeted Therapies Research And Consulting Center Sprl | Multi-ingredient pharmaceutical composition for use in cancer therapy |
JP6439931B2 (en) | 2015-02-26 | 2018-12-19 | 大日本印刷株式会社 | Adsorption conveyance device and adsorption conveyance method |
KR20180058716A (en) | 2015-10-06 | 2018-06-01 | 레드힐 바이오파마 엘티디 | Combination therapy to treat cancer |
JP2019528689A (en) | 2016-08-11 | 2019-10-17 | ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ | Immunomodulatory compounds |
EP3570856A2 (en) | 2017-01-18 | 2019-11-27 | Evelo Biosciences, Inc. | Methods of treating cancer |
EP3570857A1 (en) | 2017-01-18 | 2019-11-27 | Evelo Biosciences, Inc. | Methods of treating cancer |
CA3060510A1 (en) | 2017-04-21 | 2018-10-25 | Lunella Biotech, Inc. | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
WO2018202910A1 (en) | 2017-05-05 | 2018-11-08 | Fondazione Istituto Italiano Di Tecnologia | Combination of antibiotic and bcl-2 inhibitor and uses thereof |
MX2019013735A (en) | 2017-05-19 | 2020-01-15 | Lunella Biotech Inc | Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells. |
EP3624897A4 (en) | 2017-05-19 | 2021-07-14 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
WO2018218242A1 (en) | 2017-05-26 | 2018-11-29 | Epicentrx, Inc. | Methods and compositions for combination therapy |
AU2018373053C1 (en) | 2017-11-24 | 2021-04-01 | Lunella Biotech, Inc. | Triphenylphosphonium-derivative compounds for eradicating cancer stem cells |
EP3728300A4 (en) | 2017-12-20 | 2021-08-11 | Lunella Biotech, Inc. | Targeting mitochondrial fission through mdivi-1 derivatives |
-
2018
- 2018-04-20 EP EP18787729.5A patent/EP3612177A4/en active Pending
- 2018-04-20 US US16/606,849 patent/US11229657B2/en active Active
- 2018-04-20 CA CA3060509A patent/CA3060509A1/en active Pending
- 2018-04-20 WO PCT/US2018/028601 patent/WO2018195446A1/en active Search and Examination
-
2021
- 2021-12-13 US US17/549,475 patent/US20220096502A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070191935A1 (en) * | 2006-02-06 | 2007-08-16 | Conor Medsystems, Inc. | Drug Delivery Stent with Extended In Vivo Drug Release |
US20120258937A1 (en) * | 2011-04-08 | 2012-10-11 | Fox Chase Cancer Center | Targeting Estrogen Receptors in the Treatment of Lymphangioleiomyomatosis |
US20150335609A1 (en) * | 2012-02-17 | 2015-11-26 | Pharmacyclics, Inc. | Combinations of histone deacetylase inhibitor and pazopanib and uses thereof |
WO2014029016A1 (en) * | 2012-08-24 | 2014-02-27 | University Health Network | Compositions comprising a glycylcycline and a tyrosine kinase inhibitor for treating cancer |
US20160228399A1 (en) * | 2013-11-01 | 2016-08-11 | Pitney Pharmaceuticals Pty Limited | Pharmaceutical combinations for the treatment of cancer |
US11229657B2 (en) * | 2017-04-21 | 2022-01-25 | Lunella Biotech, Inc. | Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy |
Non-Patent Citations (1)
Title |
---|
Su et al., "Doxycycline enhances the inhibitory effects of bevacizumab on corneal neovascularization and prevents its side effects," Invest. Ophthalmol. Vis. Sci. 52(12):9108-15. PMID: 22039247. (Year: 2011) * |
Also Published As
Publication number | Publication date |
---|---|
CA3060509A1 (en) | 2018-10-25 |
US11229657B2 (en) | 2022-01-25 |
US20200046740A1 (en) | 2020-02-13 |
WO2018195446A1 (en) | 2018-10-25 |
EP3612177A1 (en) | 2020-02-26 |
EP3612177A4 (en) | 2021-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220096502A1 (en) | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy | |
De Francesco et al. | Vitamin C and Doxycycline: A synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs) | |
De Francesco et al. | Targeting hypoxic cancer stem cells (CSCs) with Doxycycline: Implications for optimizing anti-angiogenic therapy | |
Sun et al. | Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation | |
Wang et al. | Branched-chain amino acid aminotransferase 2 regulates ferroptotic cell death in cancer cells | |
US11197872B2 (en) | Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs) | |
Sun et al. | Metallothionein‐1G facilitates sorafenib resistance through inhibition of ferroptosis | |
Liu et al. | NRF2 regulates the sensitivity of human NSCLC cells to cystine deprivation-induced ferroptosis via FOCAD-FAK signaling pathway | |
Harder et al. | Brusatol overcomes chemoresistance through inhibition of protein translation | |
Tang et al. | Blockade of glutathione metabolism in IDH1-mutated glioma | |
Oliva et al. | Identification of small molecule inhibitors of human cytochrome c oxidase that target chemoresistant glioma cells | |
US11559527B2 (en) | Targeting mitochondrial fission through mDIVI-1 derivatives | |
Ye et al. | The role of Nrf2 in protection against Pb-induced oxidative stress and apoptosis in SH-SY5Y cells | |
Funes et al. | Oncogenic transformation of mesenchymal stem cells decreases Nrf2 expression favoring in vivo tumor growth and poorer survival | |
Jiang et al. | Hypoxia promotes mitochondrial glutamine metabolism through HIF1α-GDH pathway in human lung cancer cells | |
Zhang et al. | Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells | |
WO2016111991A1 (en) | The protein kinase activity of phosphoglycerate kinase 1 as a target for cancer treatment and diagnosis | |
Leung et al. | 3′-Phosphoadenosine 5′-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents | |
Jaggupilli et al. | Metabolic stress induces GD2+ cancer stem cell-like phenotype in triple-negative breast cancer | |
Jiang et al. | A CRISPR screen identifies redox vulnerabilities for KEAP1/NRF2 mutant non-small cell lung cancer | |
Zhang et al. | Arginase 1 expression is increased during hepatic stellate cell activation and facilitates collagen synthesis | |
EP3813949B1 (en) | Energetic" cancer stem cells (e-cscs): a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energy | |
Hayman et al. | Competitive but not allosteric mTOR kinase inhibition enhances tumor cell radiosensitivity | |
Fang et al. | RMI1 contributes to DNA repair and to the tolerance to camptothecin | |
Kaur et al. | DMA, a bisbenzimidazole, offers radioprotection by promoting NFκB transactivation through NIK/IKK in human glioma cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: LUNELLA BIOTECH, INC., CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LISANTI, MICHAEL P.;SOTGIA, FEDERICA;REEL/FRAME:058594/0665 Effective date: 20180420 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |